Figure 6.

TCL1 Enhances Glycolysis through AKT Activation

(A) Cell growth of iPSCs(Low-K) and iPSCs(High-K). One hundred cells of iPSCs(Low-K) or iPSCs(High-K) were passaged to 24-well plate and cell number was counted every day from day 1. Data represent means ± SEM of three independent experiments.

(B) Different colors of the cell culture media of iPSCs(Low-K) and iPSCs(High-K). 1 × 10³ cells of iPSCs(Low-K) and iPSCs(High-K) were cultured for 2 days.

(C and D) Glucose uptake (C) or lactate production (D) in iPSCs(Low-K), iPSCs(High-K), or iPSCs(High-K) with an AKT inhibitor (High-K + MK), iPSCs(Low-K) expressing TCL1 (Low-K + TCL1), or Low-K + TCL1 with an AKT inhibitor (Low-K + TCL1+MK) at day 30. Data represent means ± SEM of three independent experiments. ^∗p < 0.05, ^∗∗∗p < 0.005.

(E) Key proteins in the glycolytic pathway.

(F) The mRNA levels of glycolysis-related genes in the reprogrammed cells at day 30. Data represent means ± SEM of three independent experiments. ^∗p < 0.05 versus iPSCs(Low-K).

See also Figures S5, S6, and S7 and Table S1.